Cellectis S.A. (CLLS) Analysts See $-0.67 EPS on March, 11

Cellectis S.A. (NASDAQ:CLLS) Corporate Logo

Earnings report for Cellectis S.A. (NASDAQ:CLLS) is expected on March, 11., RTT reports. Analysts predict 11.84 % diference or $-0.67 from the $-0.76 EPS from 2018. Wall Street now sees 24.07 % negative EPS growth despite Cellectis S.A. previous quarter’s EPS of $-0.54. CLLS hit $16.93 during the last trading session after $0.11 change.Currently Cellectis S.A. is downtrending after 21.71% change in last February 12, 2018. CLLS has also 78,583 shares volume. CLLS underperformed the S&P 500 by 21.71%.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France.The company has $719.89 million market cap. The firm operates through two divisions, Therapeutics and Plants.Last it reported negative earnings. The Company’s lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia and CLL.

For more Cellectis S.A. (NASDAQ:CLLS) news announced briefly go to: Seekingalpha.com, Fool.com, Businesswire.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Genomic Medicine: Catch The Gene Therapy Wave – Seeking Alpha” announced on May 14, 2018, “Is Cellectis SA Stock a Buy Now? – The Motley Fool” on April 07, 2018, “Cellectis Appoints William Monteith as Senior Vice President U.S. Manufacturing – Business Wire” with a publish date: December 10, 2018, “Your Daily Pharma Scoop: Cellectis Trial Protocol, Tesaro Takeover Rumor, Kitov Down Before PDUFA – Seeking Alpha” and the last “Cellectis: Will Focus On Universal CAR-T Payoff? – Seeking Alpha” with publication date: May 21, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.